ARK Genomic Revolution ETF

ARKG
ETF Ticker

+77.08%

+62.09%

NYSE Arca Exchange

Equity

Global

Thematic

ETF Strategy Fund Grade AA

The ARK Genomic Revolution ETF, ARKG_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NYSE Arca Exchange and has assets under management of $2,040.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Oct 31, 2014. It has a net expense ratio of 75bps. (All data in USD as of Oct 9, 2026 unless stated.)

The investment strategy governing the actively managed ARK Genomic Revolution ETF focuses on listed companies advancing genomics across enabling tools, targeted therapeutics, molecular diagnostics, bioinformatics, and related precision medicine value chains. The portfolio invests primarily in equity securities of issuers developing or benefiting from gene editing, next generation sequencing, antibody platforms, cell and gene therapies, and computational biology; it may invest globally through common stock and depositary receipts but is generally focused on the US market. Security selection is research driven, combining bottom up fundamental work with technical and scientific diligence to assess platform scalability, clinical and regulatory milestones, unit economics, and data moats. Portfolio construction is conviction weighted within a non diversified structure, with position sizes reflecting thesis strength, liquidity, and downside scenarios. The manager monitors investability, trading depth, and corporate events, rebalancing opportunistically and trimming or exiting when the thesis changes, execution lags, risks rise, or better risk reward candidates emerge.

ETF Details

Key Facts

Issuer:
Ark Investment Management
AUM:
$2,040.0m (as of Aug 31, 2026)
Net Expense Ratio:
75 bps
Inception Date:
Oct 31, 2014
Index:
Actively managed strategy
Dividend Frequency:
Annually

Trading

Ticker:
ARKG
Exchange:
NYSE Arca Exchange
ISIN:
US00214Q3020
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Developed Markets
1 Year Volatility:
46.12%
3 Year Volatility:
44.85%
5 Year Volatility:
46.93%

Performance

TTM Dividend Yield:
0.00% (verify with issuer)
1 Month Performance:
10.78%
3 Month Performance:
19.30%
6 Month Performance:
89.51%
1 Year Performance:
62.09%
3 Year Performance:
96.03%
5 Year Performance:
-28.18%
Investment Proposition

ARK Genomic Revolution ETF (ARKG) targets companies advancing precision medicine across gene editing, sequencing, targeted therapeutics, diagnostics and enabling bioinformatics. The actively managed approach seeks capital appreciation by emphasizing platforms with large addressable markets and improving unit economics as scientific workflows scale; portfolio sizing reflects conviction in differentiated pipelines and tool providers. Exposures often lean toward earlier-stage healthcare innovators with binary clinical and regulatory catalysts, tilting factor profiles toward growth and idiosyncratic risk while pairing with established enablers to moderate liquidity needs. It can serve as a thematic mandate for healthcare innovation, a satellite growth sleeve complementing core healthcare, or a sandbox sleeve for R&D-driven optionality. Most suitable are allocators with tolerance for trial outcomes and reimbursement dynamics, and institutions pursuing long-horizon innovation budgets within policy-aware guardrails. The strategy tends to benefit when capital markets support R&D investment, regulatory pathways are constructive, and productivity gains reduce sequencing and development costs; it can face headwinds amid funding stress or clinical setbacks. A key fund-specific consideration is potential concentration in select platforms and elevated turnover, which can amplify dispersion across catalysts and increase trading costs.

ETF Analytics

Fund Discovery

4 Suggestions